结肠癌患者凝血、抗凝、纤溶指标检测及其临床意义  

Measurement of Blood Coagulation,Anticoagulant and Fibrinolytic in Patients with Colon Cancer and Its Clinical Significance

作　　者：陈君[1] 郑晓莉[1] 刘蕊[1] 

机构地区：[1]天津市人民医院检验学部,300121

出　　处：《天津医药》2006年第9期605-606,共2页Tianjin Medical Journal

摘　　要：目的:探讨结肠癌患者凝血、抗凝、纤溶指标的变化与其病理分型、分化程度、转移及患者预后的关系。方法:结肠癌患者109例,对照组41例。检测凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、抗凝血酶(AT)、D-二聚体(D-Dimer)。结果:PT、APTT随病情加重稍有延长但各组间差异无统计学意义(P>0.05);FIB、D-Dimer随病情加重而增高,AT随病情加重活性逐渐降低,此3项指标各组间差异均有统计学意义(P<0.05)。结论:结肠癌患者存在明显的凝血、抗凝及纤溶机制的异常且其变化与病情发展及预后有关。Objective： To explore the relationship between the changes of blood coagulation, anticoagulant and fibrinolytic parameters and their pathological types, differentiation degree and metastasis in patients with colon cancer. Methods： One hundred and nine patients were with colon cancer, and 41 healthy individuals were as control. Prothrombin time （PT）, activated partial thromboplastin time （APTT）, fibrinogen （FIB）, antithrombin （AT） and D-Dimer were detected in all patients and control group. Results： There were no significant differences in PT and APTT activity between the two groups （P 〉 0.05）. The plasma level of FIB and D-Dimer increased, AT activity decreased progressively with the exacerbation of colon cancer, and there was a significant difference between the two groups （P 〈 0.05）. Conclusion： There are abnormal FIB, D-Dimer and AT in patients with colon cancer. Their changes are closely related with the progression of patient＇ s condition and prognosis.

关 键 词：结肠肿瘤 癌 凝血酶原时间 部分促凝血酶原时间 纤维蛋白原 抗凝血酶类 

分 类 号：R446.11[医药卫生—诊断学] R973.2[医药卫生—临床医学]